Bristol, Acceleron Anemia Treatment Gets Nod From Euro Regulators

Bristol Myers Squibb Co. and Acceleron Pharma Inc. said Thursday that a European Medicines Agency’s committee has recommended the approval of its anemia treatment for adults.
The regulator’s Committee for Medicinal Products for Human Use issued a positive opinion of the advanced Phase 3 trial of Reblozyl.
Reblozyl treats adult patients with transfusion-dependent anemia due to either low to intermediate myelodysplastic syndrome, a group of bone marrow failure disorders, or beta thalassemia, a blood disorder that reduces hemoglobin production.
“If approved, Reblozyl would be the first erythroid maturation agent approved in the EU, representing a new class of therapy for eligible patients,” the companies said.

https://www.marketscreener.com/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Squibb-Acceleron-Pharma-s-Anemia-Treatment-Gets-Nod-From-European-Regulator-30508146/